These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 11853286

  • 1. Difference in bone acquisition among hormonally treated postmenopausal women with normal and low bone mass.
    Taechakraichana N, Jaisamrarn U, Panyakhamlerd K, Chaikittisilpa S, Limpaphayom K.
    J Med Assoc Thai; 2001 Oct; 84 Suppl 2():S586-92. PubMed ID: 11853286
    [Abstract] [Full Text] [Related]

  • 2. Bone mineral density and history of oral contraceptive use.
    Fortney JA, Feldblum PJ, Talmage RV, Zhang J, Godwin SE.
    J Reprod Med; 1994 Feb; 39(2):105-9. PubMed ID: 8169923
    [Abstract] [Full Text] [Related]

  • 3. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
    Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR.
    Maturitas; 2008 Jan 20; 59(1):2-6. PubMed ID: 18063490
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2007 Jul 20; 23(7):398-403. PubMed ID: 17701771
    [Abstract] [Full Text] [Related]

  • 5. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE, Bjarnason NH, Neven P, Plouffe L, Johnston CC, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.
    Menopause; 2003 Jul 20; 10(4):337-44. PubMed ID: 12851517
    [Abstract] [Full Text] [Related]

  • 6. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
    Bagger YZ, Tankó LB, Alexandersen P, Hansen HB, Møllgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C.
    Bone; 2004 Apr 20; 34(4):728-35. PubMed ID: 15050905
    [Abstract] [Full Text] [Related]

  • 7. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
    Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, Stych B, Melton ME.
    Arch Intern Med; 2003 Apr 14; 163(7):789-94. PubMed ID: 12695269
    [Abstract] [Full Text] [Related]

  • 8. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A.
    Ann Acad Med Stetin; 2003 Apr 14; 49():111-30. PubMed ID: 15552843
    [Abstract] [Full Text] [Related]

  • 9. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M, Theppisai U, Manonai J, Suchartwatnachai C, Jorgensen LN.
    Acta Obstet Gynecol Scand; 2003 Sep 14; 82(9):857-66. PubMed ID: 12911449
    [Abstract] [Full Text] [Related]

  • 10. The relationship between serum dehydroepiandrosterone sulfate concentration and bone mineral density, lipids, and hormone replacement therapy in premenopausal and postmenopausal women.
    Osmanagaoglu MA, Okumuş B, Osmanagaoglu T, Bozkaya H.
    J Womens Health (Larchmt); 2004 Nov 14; 13(9):993-9. PubMed ID: 15665656
    [Abstract] [Full Text] [Related]

  • 11. The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women.
    Maddalozzo GF, Widrick JJ, Cardinal BJ, Winters-Stone KM, Hoffman MA, Snow CM.
    Bone; 2007 May 14; 40(5):1244-51. PubMed ID: 17291843
    [Abstract] [Full Text] [Related]

  • 12. [Absence of antiosteopenic effect of hormone replacement therapy in postmenopausal women].
    Ortiz Núñez DA, Mengchún López G, Hernández Marín I, Mendoza R, Ayala Ruíz AR.
    Ginecol Obstet Mex; 2004 Jul 14; 72():349-55. PubMed ID: 15469174
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy.
    Song EK, Yeom JH, Shin HT, Kim SH, Shin WG, Oh JM.
    J Clin Pharm Ther; 2006 Oct 14; 31(5):421-7. PubMed ID: 16958819
    [Abstract] [Full Text] [Related]

  • 14. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW, Bodmer C, Senn C, Fuchs G, Kraenzlin ME, Wyss H, Birkhaeuser MH, Lippuner K.
    Maturitas; 2006 Jan 20; 53(2):191-200. PubMed ID: 16368472
    [Abstract] [Full Text] [Related]

  • 15. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY.
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct 20; 31(6):541-9. PubMed ID: 12407324
    [Abstract] [Full Text] [Related]

  • 16. [Effects of long-term and low-dose hormone replacement therapy on bone mineral density in postmenopausal women].
    Nie M, Sun ML, Ge QS.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun 20; 28(3):421-4. PubMed ID: 16900649
    [Abstract] [Full Text] [Related]

  • 17. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy.
    Milliken LA, Going SB, Houtkooper LB, Flint-Wagner HG, Figueroa A, Metcalfe LL, Blew RM, Sharp SC, Lohman TG.
    Calcif Tissue Int; 2003 Apr 20; 72(4):478-84. PubMed ID: 12574871
    [Abstract] [Full Text] [Related]

  • 18. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S, Caubel P, Garnero P, Felsenberg D.
    Maturitas; 2004 Jul 15; 48(3):197-207. PubMed ID: 15207885
    [Abstract] [Full Text] [Related]

  • 19. Effect of parity on bone mineral density among postmenopausal Saudi Arabian women.
    Sadat-Ali M, Al-Habdan I, Al-Mulhim AA, El-Hassan AY.
    Saudi Med J; 2005 Oct 15; 26(10):1588-90. PubMed ID: 16228061
    [Abstract] [Full Text] [Related]

  • 20. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L, Ravn P, Christiansen C.
    Maturitas; 2005 Feb 14; 50(2):78-85. PubMed ID: 15653003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.